A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumours

Trial Profile

A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumours

Discontinued
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Omipalisib (Primary) ; Trametinib (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 03 Mar 2015 Status changed from active, no longer recruiting to discontinued, according to ClinicalTrials.gov record.
    • 09 Feb 2015 Planned End Date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
    • 09 Feb 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top